Adventus Mining
CVE:ADZNAdventus Mining Corporation engages in the acquisition, exploration, and development of mineral properties in Ecuador, Canada, and Ireland. The company explores for copper, gold, zinc, lead, silver, molybdenum, and tungsten deposits. Its principal project is the Curipamba property covering an area of 21,500 hectares located in Ecuador. The company was formerly known as Adventus Zinc Corporation and changed its name to Adventus Mining Corporation in June 2019. Adventus Mining Corporation was incorporated in 2016 and is headquartered in Toronto, Canada.
Aurania Resources
CVE:ARUAurania Resources Ltd., a junior exploration mining company, engages in the identification, evaluation, acquisition, and exploration of mineral properties in Ecuador and Peru. The company explores for gold, silver, copper, and other precious metal deposits. Its flagship project is the 100% owned Lost Cities Cutucu project comprises 42 mineral exploration concessions covering an area of approximately 207,764 hectares located in southeastern Ecuador. The company was formerly known as Urania Resources Ltd. and changed its name to Aurania Resources Ltd. in March 2012. Aurania Resources Ltd. was founded in 2001 and is headquartered in Toronto, Canada.
Colabor Group
TSE:GCLColabor Group Inc., together with its subsidiaries, markets and distributes food and food-related products in Canada. It operates in two segments, Distribution and Wholesale. The Distribution segment offers frozen products, dry staples, dairy products, meat, fish, seafood, fruits and vegetables, disposables, and sanitation products. This segment serves restaurants, hotels, foodservice operators, specialty food stores, healthcare institutions, schools and universities, and other retail customers. The Wholesale segment provides food, general food-related, and non-food products to distributors, food service, and retail industries. Colabor Group Inc. was founded in 1962 and is headquartered in Boucherville, Canada.
Mylan
NASDAQ:MYLMylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.